Cardiovascular disease and hematologic malignancies frequently intersect, creating complex clinical scenarios for Indian physicians. Heart failure (HF) often coexists with Philadelphia-negative myeloproliferative neoplasms (MPNs), yet traditional models frequently underestimate the HF-MPNs cardiovascular risk in this population. Chronic inflammation and clonal hematopoiesis act as catalysts, accelerating myocardial damage and thrombotic events. Consequently, a more integrated approach is required to manage these high-risk cardio-oncology patients effectively.

Integrated Biomarkers for HF-MPNs Cardiovascular Risk

In the diagnostic phase, natriuretic peptides (BNP/NT-proBNP) and cardiac troponins remain fundamental for acute assessment. However, refining the HF-MPNs cardiovascular risk requires looking beyond standard cardiac markers. Emerging biomarkers such as soluble ST2, galectin-3, and GDF-15 offer superior long-term prognostic value by reflecting underlying fibrotic and inflammatory processes.

Furthermore, hematologic variables play a critical role in cardiovascular outcomes. Clinicians should monitor driver mutations—specifically JAK2, CALR, and MPL—as these genetic markers independently correlate with increased thrombotic risk. When combined with traditional blood counts and LDH levels, these markers provide a comprehensive view of the patient's cardio-hematologic status. Additionally, advanced imaging techniques like global longitudinal strain (GLS) and cardiac magnetic resonance (CMR) characterize tissue changes more accurately than simple ejection fraction measurements.

The 0-8 Point Hybrid Algorithm for Risk Stratification

A significant development in this field is the proposal of a pragmatic 0-8-point composite algorithm. This framework seeks to harmonize cardiology and hematology by combining established HF models, such as MAGGIC or SHFM, with MPN-specific risk factors like leukocytosis and driver mutation status. By identifying high-risk phenotypes early, especially in ACC/AHA Stages A through C, clinicians can implement more rigorous cardio-oncology surveillance. This structured follow-up is particularly relevant in India, where the dual burden of cardiovascular disease and cancer continues to rise.

FAQs on HF and MPN Management

How do JAK2 mutations specifically impact heart failure?

JAK2 mutations promote a pro-inflammatory environment and alter blood rheology, which increases the likelihood of microvascular dysfunction and thrombotic complications, directly contributing to heart failure progression.

Why is multimodality imaging recommended over standard echocardiography?

Standard echocardiography often misses early myocardial strain. Advanced tools like global longitudinal strain (GLS) and CMR tissue characterization provide a more nuanced understanding of subclinical damage before the ejection fraction drops.

What are the key components of the proposed 0-8 point score?

The score integrates cardiac biomarkers (natriuretic peptides/troponins), validated HF risk scores, MPN driver mutations, blood counts (leukocytosis/thrombocytosis), and LDH levels to stratify risk levels.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Muraretu IR et al. Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores - a narrative review. Cardiooncology. 2026 Jun 06. doi: 10.1186/s40959-026-00518-7. PMID: 42251458.

2. Leiva O, et al. Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(2):161-182.

3. Lyon AR, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA). Eur Heart J. 2022;43(41):4229-4361.

"